The £2-pro day medicine, the cardiac infarct risk to lower can
Thousands of heart attack patients will profit from a £2-pro day medicine, after by the authorities one recommended to give this to more people for a longer period.
The coagulate-restraining medicine Ticagrelor reduces the risk of repetitive cardiac infarcts for people with a heart illness.
The medicine is given already 12 months long after a cardiac infarct, whereby the risk of an apoplexy or a further cardiac infarct is reduced.
The regulatory authority NICE of NHS recommended a four years long income, in order to reduce the risk of cardiovascular problems further.
The regulatory authority NICE of NHS recommended a four years long income, in order to reduce the risk of cardiovascular problems further.
Approximately 140,000 people suffer each year a cardiac infarct and a quarter of it suffer a further cardiac infarct or an apoplexy.
Cardiac infarcts and apoplexies are caused by accumulations of fatty material in the arterial walls, which form surfaces.
If the surface breaks apart, it can cause a blood clot, which causes flow of blood up to the heart clogged and thus a cardiac infarct.
If the blood clot separates, it can flow by the bloodstream and clog flow of blood to the brain, which causes an apoplexy.
People, who had already a cardiac infarct, are subject to a higher risk a further to have.
Ticagrelor, which is manufactured by the British enterprise AstraZeneca and under the trade name Brilique is driven out, reduces this risk, by making the formation of blood clots more improbable.
The instruction draft of NICE, which was today published, recommends a 12-month income of 90mg Ticagrelor, followed from 60mg with a twice daily income of Aspirin for the next three years.
Professor Carole Longson, Direktorin of the NICE of health technology evaluation center said: “A quarter of all people, who suffered a cardiac infarct, has defiance of the availability of secondary prevention a further cardiac infarct or an apoplexy - often with disastrous consequences.”
The fear of a renewed cardiac infarct can have substantial negative effects on the quality of life of a person.
The experience shows that Ticagrelor is effective in combination with Aspirin with the reduction of further cardiac infarcts and apoplexies at people, which had already a cardiac infarct.
By a provisional recommendation of Ticagrelor we are pleased that we are able to extend available treatment options to thousands of humans who can profit from it.
The information about the effectiveness and security of Ticagrelor - above all the bleeding risk - are limited to one period of up to three years. The instruction draft does not recommend treatment, which goes beyond this period.
